Executive Summary: A Paradigm Shift in Retinal Care
Recent data presented at the American Society of Retina Specialists (ASRS) meeting in Montreal have provided compelling evidence that the complement inhibitor pegcetacoplan (Syfovre) is a versatile therapeutic tool for patients suffering from geographic atrophy (GA). While traditionally studied in the context of standalone GA, new research indicates that the drug’s ability to slow the progression of retinal cell loss—specifically regarding the retinal pigment epithelium (RPE) and photoreceptors (PR)—extends to patients who also suffer from neovascular age-related macular degeneration (nAMD).
The findings, derived from extensive real-world evidence and propensity-matched analyses, suggest that pegcetacoplan may offer neuroprotective benefits that persist even when administered alongside standard anti-VEGF (vascular endothelial growth factor) therapies. For clinicians, this marks a potential turning point in managing the complex, often overlapping phenotypes of advanced age-related macular degeneration.
The Chronology of Research and Clinical Discovery
The journey toward understanding the utility of pegcetacoplan in complex retinal cases began with the fundamental realization that GA rarely exists in a vacuum. A landmark study, which analyzed data from approximately 13,000 treated eyes, revealed that nearly 25% of patients presenting with GA were simultaneously receiving treatment for nAMD. This realization prompted researchers to move beyond the clinical trial environments of early drug approval and into the "real-world" data landscape.
Following this initial epidemiological observation, investigators sought to quantify how pegcetacoplan behaved in these dual-diagnosis patients. By utilizing advanced artificial intelligence platforms—specifically the RetinAI Discovery software—researchers were able to perform high-resolution, longitudinal analyses of optical coherence tomography (OCT) scans.
The most recent presentations at the 2025 ASRS meeting represent the culmination of this two-pronged investigative effort:
- The Al-khersan Study: Focused on the structural changes (RPE and PR loss) in patients with GA alone versus those with GA and concurrent nAMD.
- The Patel Analysis: A propensity-matched study evaluating long-term visual acuity outcomes and the potential synergistic effects of combining pegcetacoplan with anti-VEGF therapy.
Supporting Data: Structural and Functional Efficacy
The strength of these findings lies in the consistency of the results across multiple patient cohorts. The data demonstrates that pegcetacoplan is not merely effective in isolation; its therapeutic footprint appears to be robust even in the presence of more aggressive disease states.
Structural Preservation: RPE and Photoreceptors
Dr. Hasenin Al-khersan of the Retina Group of Florida reported on a cohort of 497 eyes (240 with GA alone, 257 with GA and concurrent nAMD). By comparing 12-month pretreatment data to 12-month post-initiation data, the study revealed a significant slowing of atrophy progression.
- RPE Loss: In eyes with GA alone, the rate of RPE loss slowed by 23%. Notably, in the concurrent nAMD cohort, the protection was even more pronounced, with the rate of RPE loss slowing by 40%.
- Photoreceptor Loss: Protection against photoreceptor loss followed a similar trend. Eyes with GA alone saw a 41% reduction in the rate of PR loss, while those with concurrent nAMD experienced a 58% reduction.
These results were corroborated by objective metrics: the annualized rate of RPE loss in the post-treatment phase was 0.96 mm² for the combined-disease group, compared to 1.17 mm² for the GA-only group, indicating that the drug may have a heightened impact in eyes already under management for neovascular processes.
Functional Outcomes: Visual Acuity and Long-term Vision
The analysis led by Dr. Nimesh Patel of Mass Eye and Ear provided the necessary clinical correlate: the functional impact on the patient’s sight. By utilizing a propensity-score matching model that accounted for age, gender, baseline visual acuity, and lesion characteristics, the researchers ensured a fair comparison between treated and control groups.
The findings were striking:
- BCVA Preservation: Patients treated with pegcetacoplan maintained better best-corrected visual acuity (BCVA) than those in the control groups.
- Synergy with Anti-VEGF: In the cohort receiving both pegcetacoplan and anti-VEGF therapy, the preservation of visual acuity was statistically significant at all measured time points compared to those receiving anti-VEGF alone.
- Prevention of Severe Loss: A critical threshold in retinal care is the loss of 15 or more letters of vision. The data showed that significantly fewer patients treated with pegcetacoplan reached this milestone of severe vision loss compared to their respective control groups, with benefits persisting for up to 18 months.
Official Responses and Expert Interpretation
The retina community has responded with cautious optimism. Experts at the ASRS meeting emphasized that these results address a significant "knowledge gap" regarding real-world patient management.
"This is something we’re going to have to think about, as a field," noted Dr. Nimesh Patel during the conference. He emphasized that as the population ages and the prevalence of combined GA/nAMD increases, clinicians must move toward evidence-based management strategies that prioritize both the structural integrity of the retina and the preservation of central vision.
Dr. Hasenin Al-khersan highlighted that while the drug showed more pronounced numerical effects in the combined-disease cohort, the consistent slowing of atrophy across all groups validates the drug’s mechanism of action—the modulation of the complement cascade—as a foundational strategy in retinal disease management.
Furthermore, the integration of artificial intelligence in these studies was praised as a new standard for research. By removing subjective bias from the measurement of atrophy on OCT scans, platforms like RetinAI Discovery have provided a level of precision that was previously difficult to achieve in clinical practice studies.
Implications for Clinical Practice
The implications of these findings are profound for both the ophthalmology community and the patients they serve.
Redefining the Standard of Care
Historically, patients with both nAMD and GA have been difficult to treat, as the focus was almost exclusively on managing the neovascular activity via anti-VEGF injections. These new data suggest that adding pegcetacoplan is not only safe but provides a measurable benefit in slowing the "background" atrophy that often leads to irreversible vision loss.
A Data-Driven Approach to Treatment
The use of propensity-matched analyses provides clinicians with a higher degree of confidence when discussing treatment plans with patients. For a patient already receiving monthly or bi-monthly anti-VEGF injections, the addition of pegcetacoplan can be framed not just as an additional burden, but as a proactive strategy to preserve the remaining retinal architecture.
Future Research Directions
While these findings are highly encouraging, experts agree that further studies are required. Questions remain regarding the optimal frequency of administration, the long-term cost-benefit ratio for healthcare systems, and whether specific patient subsets—based on genetic predispositions or initial lesion topography—might benefit more than others.
However, the current evidence points to a clear trajectory: the complement inhibitor platform, once limited to a narrow scope of GA patients, is emerging as a cornerstone of modern retinal therapy. The ability to effectively "dual-treat" patients who face the compounded challenge of both neovascularization and cellular atrophy represents a significant advancement in the fight against blindness.
Conclusion
The data presented at ASRS 2025 signals a maturing understanding of geographic atrophy. By moving beyond the binary view of GA as a standalone condition, clinicians are discovering that pegcetacoplan offers a protective shield against the relentless progression of retinal degradation. Whether a patient presents with GA alone or in the complex context of neovascular AMD, the evidence suggests that the complement inhibition pathway remains a vital target for preserving visual function. As the field looks toward the future, these real-world insights will undoubtedly shape clinical protocols, ensuring that more patients retain their independence and quality of life for longer periods.
